Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
К вопросу о рациональном выборе топической терапии при атопическом дерматите
К вопросу о рациональном выборе топической терапии при атопическом дерматите
Дворянкова Е.В., Корсунская И.М., Сакания Л.Р., Невозинская З.А. К вопросу о рациональном выборе топической терапии при атопическом дерматите. Consilium Medicum. Pediatrics (Suppl.). 2015; 1: 70–74.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье приведены современные данные о механизмах развития атопического дерматита, рассматриваются разные аспекты клинических проявлений атопического дерматита у детей разного возраста, а также предлагаются подходы к терапии атопического дерматита у детей с учетом тех или иных кожных проявлений заболевания.
Ключевые слова: атопический дерматит, лечение дерматита, метилпреднизолона ацепонат.
Key words: atopic dermatitis, dermatitis treatment, methylprednisolone aceponate.
Ключевые слова: атопический дерматит, лечение дерматита, метилпреднизолона ацепонат.
________________________________________________
Key words: atopic dermatitis, dermatitis treatment, methylprednisolone aceponate.
Полный текст
Список литературы
1. Amestejani M, Salehi BS, Vasigh M et al. Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study. J Drugs Dermatol 2012; 11: 327–30.
2. Kapoor R, Menon C, Hoffstad O et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008; 58: 68–73.
3. Weber MB, Lorenzini D, Reinehr CP, Lovato B. Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras Dermatol 2012; 87: 697–702.
4. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitisis associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151–8.
5. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233–46.
6. Dold S, Wjst M, von Mutius E et al. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992; 67: 1018–22.
7. Carlsen BC, Thyssen JP, Menne T et al. Association between filaggrin null mutations and concomitant atopic dermatitis and contact allergy. Clin Exp Dermatol 2011; 36: 467–72.
8. Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131: 295–9.
9. Freiberg IM, Eisen AZ, Wolff K et al. Fitzpatrick's Dermatology in general medicine. 6th ed. V. 1. New York: McGraw Hill, 2003; p. 1464.
10. Froebe CL, Simion A, Ohlmeyer H et al. Prevention od stratum corneum lipid phase transitions in vitro by glycerol – an alternative mechanism for skin moisturisation. J Soc Cosmet Chem 1990: 41: 51–65
11. Йоффе Д.В. Жиры. В кн.: Химическая энциклопедия. М.: Советская энциклопедия, 1990; с. 155–7. / Ioffe D.V. Zhiry. V kn.: Khimicheskaia entsiklopediia. M.: Sovetskaia entsiklopediia, 1990; s. 155–7. [in Russian]
12. Fulton J Jr. Comedogenicity and irritancy of commonly used ingredients. J Soc Cosmet Сhem 1989; 40: 321–33.
13. Nguyen SH, Dang TP, Maibach HI. Comedogenicity in rabbit: some cosmetic ingredients/vehicles. Cutan Ocul Toxicol 2007; 26: 287–92.
14. Блюм-Пейтави У. Особенности течения и дифференциальная диагностика атопического дерматита у детей. Consilium Medicum. Педиатрия (Прил.). 2014; 1: 27–30. / Blium-Peitavi U. Osobennosti techeniia i differentsial'naia diagnostika atopicheskogo dermatita u detei. Consilium Medicum. Pediatriia (Pril.). 2014; 1: 27–30. [in Russian]
2. Kapoor R, Menon C, Hoffstad O et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008; 58: 68–73.
3. Weber MB, Lorenzini D, Reinehr CP, Lovato B. Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras Dermatol 2012; 87: 697–702.
4. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitisis associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151–8.
5. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233–46.
6. Dold S, Wjst M, von Mutius E et al. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992; 67: 1018–22.
7. Carlsen BC, Thyssen JP, Menne T et al. Association between filaggrin null mutations and concomitant atopic dermatitis and contact allergy. Clin Exp Dermatol 2011; 36: 467–72.
8. Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131: 295–9.
9. Freiberg IM, Eisen AZ, Wolff K et al. Fitzpatrick's Dermatology in general medicine. 6th ed. V. 1. New York: McGraw Hill, 2003; p. 1464.
10. Froebe CL, Simion A, Ohlmeyer H et al. Prevention od stratum corneum lipid phase transitions in vitro by glycerol – an alternative mechanism for skin moisturisation. J Soc Cosmet Chem 1990: 41: 51–65
11. Ioffe D.V. Zhiry. V kn.: Khimicheskaia entsiklopediia. M.: Sovetskaia entsiklopediia, 1990; s. 155–7. [in Russian]
12. Fulton J Jr. Comedogenicity and irritancy of commonly used ingredients. J Soc Cosmet Сhem 1989; 40: 321–33.
13. Nguyen SH, Dang TP, Maibach HI. Comedogenicity in rabbit: some cosmetic ingredients/vehicles. Cutan Ocul Toxicol 2007; 26: 287–92.
14. Blium-Peitavi U. Osobennosti techeniia i differentsial'naia diagnostika atopicheskogo dermatita u detei. Consilium Medicum. Pediatriia (Pril.). 2014; 1: 27–30. [in Russian]
2. Kapoor R, Menon C, Hoffstad O et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008; 58: 68–73.
3. Weber MB, Lorenzini D, Reinehr CP, Lovato B. Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras Dermatol 2012; 87: 697–702.
4. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitisis associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151–8.
5. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233–46.
6. Dold S, Wjst M, von Mutius E et al. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992; 67: 1018–22.
7. Carlsen BC, Thyssen JP, Menne T et al. Association between filaggrin null mutations and concomitant atopic dermatitis and contact allergy. Clin Exp Dermatol 2011; 36: 467–72.
8. Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131: 295–9.
9. Freiberg IM, Eisen AZ, Wolff K et al. Fitzpatrick's Dermatology in general medicine. 6th ed. V. 1. New York: McGraw Hill, 2003; p. 1464.
10. Froebe CL, Simion A, Ohlmeyer H et al. Prevention od stratum corneum lipid phase transitions in vitro by glycerol – an alternative mechanism for skin moisturisation. J Soc Cosmet Chem 1990: 41: 51–65
11. Йоффе Д.В. Жиры. В кн.: Химическая энциклопедия. М.: Советская энциклопедия, 1990; с. 155–7. / Ioffe D.V. Zhiry. V kn.: Khimicheskaia entsiklopediia. M.: Sovetskaia entsiklopediia, 1990; s. 155–7. [in Russian]
12. Fulton J Jr. Comedogenicity and irritancy of commonly used ingredients. J Soc Cosmet Сhem 1989; 40: 321–33.
13. Nguyen SH, Dang TP, Maibach HI. Comedogenicity in rabbit: some cosmetic ingredients/vehicles. Cutan Ocul Toxicol 2007; 26: 287–92.
14. Блюм-Пейтави У. Особенности течения и дифференциальная диагностика атопического дерматита у детей. Consilium Medicum. Педиатрия (Прил.). 2014; 1: 27–30. / Blium-Peitavi U. Osobennosti techeniia i differentsial'naia diagnostika atopicheskogo dermatita u detei. Consilium Medicum. Pediatriia (Pril.). 2014; 1: 27–30. [in Russian]
________________________________________________
2. Kapoor R, Menon C, Hoffstad O et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008; 58: 68–73.
3. Weber MB, Lorenzini D, Reinehr CP, Lovato B. Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras Dermatol 2012; 87: 697–702.
4. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitisis associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151–8.
5. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233–46.
6. Dold S, Wjst M, von Mutius E et al. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992; 67: 1018–22.
7. Carlsen BC, Thyssen JP, Menne T et al. Association between filaggrin null mutations and concomitant atopic dermatitis and contact allergy. Clin Exp Dermatol 2011; 36: 467–72.
8. Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131: 295–9.
9. Freiberg IM, Eisen AZ, Wolff K et al. Fitzpatrick's Dermatology in general medicine. 6th ed. V. 1. New York: McGraw Hill, 2003; p. 1464.
10. Froebe CL, Simion A, Ohlmeyer H et al. Prevention od stratum corneum lipid phase transitions in vitro by glycerol – an alternative mechanism for skin moisturisation. J Soc Cosmet Chem 1990: 41: 51–65
11. Ioffe D.V. Zhiry. V kn.: Khimicheskaia entsiklopediia. M.: Sovetskaia entsiklopediia, 1990; s. 155–7. [in Russian]
12. Fulton J Jr. Comedogenicity and irritancy of commonly used ingredients. J Soc Cosmet Сhem 1989; 40: 321–33.
13. Nguyen SH, Dang TP, Maibach HI. Comedogenicity in rabbit: some cosmetic ingredients/vehicles. Cutan Ocul Toxicol 2007; 26: 287–92.
14. Blium-Peitavi U. Osobennosti techeniia i differentsial'naia diagnostika atopicheskogo dermatita u detei. Consilium Medicum. Pediatriia (Pril.). 2014; 1: 27–30. [in Russian]
Авторы
Е.В.Дворянкова1, И.М.Корсунская*1, Л.Р.Сакания1, З.А.Невозинская2
1 ФГБУН Центр теоретических проблем физико-химической фармакологии РАН. 119991, Россия, Москва, Ленинский проспект, д. 38а, корп. 1;
2 ГБУЗ Московский научно-практический центр дерматовенерологии и косметологии Департамента здравоохранения г. Москвы. 119071, Россия, Москва, Ленинский проспект, д. 17
*marykor@bk.ru
1 Center for Theoretical Problems of Physicochemical Pharmacology. 119991, Russian Federation, Moscow, Leninskiy prospekt, d. 38a, korp. 1;
2 Moscow Scientific and Practical Center of Dermatology and Venereology and Cosmetology of the Department of Health of Moscow. 119071, Russian Federation, Moscow, Leninskiy prospekt, d. 17
*marykor@bk.ru
1 ФГБУН Центр теоретических проблем физико-химической фармакологии РАН. 119991, Россия, Москва, Ленинский проспект, д. 38а, корп. 1;
2 ГБУЗ Московский научно-практический центр дерматовенерологии и косметологии Департамента здравоохранения г. Москвы. 119071, Россия, Москва, Ленинский проспект, д. 17
*marykor@bk.ru
________________________________________________
1 Center for Theoretical Problems of Physicochemical Pharmacology. 119991, Russian Federation, Moscow, Leninskiy prospekt, d. 38a, korp. 1;
2 Moscow Scientific and Practical Center of Dermatology and Venereology and Cosmetology of the Department of Health of Moscow. 119071, Russian Federation, Moscow, Leninskiy prospekt, d. 17
*marykor@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.